A multicenter, randomized, phase Ib/II trial of the oral c-Met inhibitor MSC2156119J as monotherapy versus sorafenib in Asian patients with MET-positive (MET+) advanced hepatocellular carcinoma (HCC) and Child-Pugh Class A liver function.
Shukui Qin
No relevant relationships to disclose
Ann-Lii Cheng
Consultant or Advisory Role - Bayer; Exelixis; Merck
Honoraria - Bayer; Exelixis; Merck
Research Funding - Chugai Pharma; Sanofi
Ho Yeong Lim
No relevant relationships to disclose
Lianzhe Xu
Employment or Leadership Position - Merck Serono
Friedhelm Bladt
Employment or Leadership Position - Merck KGaA
Andreas Johne
Employment or Leadership Position - Merck KGaA
Cindy Li
Employment or Leadership Position - Merck Serono
Hongxia Zheng
Employment or Leadership Position - EMD Serono
Giorgio Massimini
Employment or Leadership Position - Merck KGaA